The Non-opioid Analgesics Market to transcend the Covid-19 hump from 2021 onwards

Analgesics are the drugs used for the management of the pain. Pain is one of the most common phenomenon and around 85% of people are reported to suffer from pain worldwide at some point in their life. Pain can be of various types such as due to surgery, strain, etc. Non-opioid analgesics are the drugs which are used for relieving pain, since use of most of the opioid drugs is abused at some stage by patient or any other person for non-medical use hence usage of opioid drugs is advised to lower by various healthcare professionals. More than 56% of people across the world are reported to experience the body pain once a week whereas head pain affects around 23% once a week. More than 70,000 Americans died due to opioid abuse in 2017, which resulted in stringent regulatory measures by various regulatory bodies.

Increasing prevalence of the various chronic diseases such as cancer in which various treatments such as chemotherapy is responsible for the pain expected to drive the growth of the non-opioid analgesics market. Increasing number of surgeries is expected to result in increased prevalence of post-operative pain which in turn expected to drive the growth of the non-opioid analgesics market. Increasing number of people suffering from neuropathic pain further expected to fuel the growth of non-opioid analgesics market. Additional regulatory impositions on the opioid drugs is responsible for their limited market reach which in turn expected to drive the growth of the non-opioid analgesics market. Increasing support of various advocacy groups and KOLs to the non-opioid analgesics expected to drive the growth of the non-opioid analgesics market. Lower cost of the non-opioid analgesics as compared to opioid drugs further expected to drive the growth of the non-opioid analgesics market. Worldwide reach of various regional and global non-opioid analgesics manufacturers resulted in the easy access to these drugs driving the growth of the non-opioid analgesics market. Whereas, frequent use of non-opioid analgesics is linked to various conditions such as decreased kidney functioning, increased risk of stroke, etc. may hamper the growth of the market.

To remain ‘ahead’ of your competitors, request for a sample here@

https://www.persistencemarketresearch.com/samples/28657

The global non-opioid analgesics market is segmented based on the drug class, pain type, route of administration, distribution channel and region.

By drug class, the global non-opioid analgesics market is segmented as:

• NSAIDs
• Acetaminophen
• Local Anaesthetics

By pain type, the global non-opioid analgesics market is segmented as:

• Post-operative Pain
• Cancer Pain
• Neuropathic Pain
• Others

By route of administration, the global non-opioid analgesics market is segmented as:

• Oral
• Topical
• Injectable

By distribution channel, the global non-opioid analgesics market is segmented as:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

The global non-opioid analgesics market is expected to experience steady growth over the forecast period due to increasing prevalence of pain. By drug class, NSAIDs is expected to be the most lucrative segment in the global non-opioid analgesics market. By pain type, post-operative pain is expected to be the most revenue generating segment in global non-opioid analgesics market. By route of administration, oral is expected to be most lucrative segment in the global non-opioid analgesics market. By distribution channel, retail pharmacies is expected to be the most lucrative segment in global non-opioid analgesics market owing to higher patient footfall.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/28657

The global non-opioid analgesics market is expected to be dominated by the North America due to higher prevalence of the pain. Europe is expected to be the second most lucrative region in the global non-opioid analgesics market owing to higher adoption of the analgesics. Asia-Pacific is expected to be the fastest growing non-opioid analgesics market due to large population residing in countries such as India and China. Latin America market is expected to experience steady growth whereas MEA expected to be the least lucrative market due to lower adoption.

The key participants operating in the global non-opioid analgesics market are: Iroko Pharmaceuticals, LLC, Pfizer Inc., Johnson & Johnson, MERCK, MIPHARM S.p.A., Novartis AG, Teva Pharmaceuticals, Mylan NV, and others

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/28657

Explore Extensive Coverage of PMR`s 

Life Sciences & Transformational Health Landscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved Beg
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

Source MARKITWIRED